Monte Rosa Therapeutics (GLUE) Competitors $4.43 +0.02 (+0.45%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$4.43 0.00 (0.00%) As of 04/15/2025 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLUE vs. IOVA, SNDX, WVE, COLL, ELVN, DYN, GPCR, ETNB, CMRX, and CDMOShould you be buying Monte Rosa Therapeutics stock or one of its competitors? The main competitors of Monte Rosa Therapeutics include Iovance Biotherapeutics (IOVA), Syndax Pharmaceuticals (SNDX), Wave Life Sciences (WVE), Collegium Pharmaceutical (COLL), Enliven Therapeutics (ELVN), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), 89bio (ETNB), Chimerix (CMRX), and Avid Bioservices (CDMO). These companies are all part of the "pharmaceutical products" industry. Monte Rosa Therapeutics vs. Iovance Biotherapeutics Syndax Pharmaceuticals Wave Life Sciences Collegium Pharmaceutical Enliven Therapeutics Dyne Therapeutics Structure Therapeutics 89bio Chimerix Avid Bioservices Monte Rosa Therapeutics (NASDAQ:GLUE) and Iovance Biotherapeutics (NASDAQ:IOVA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, risk, profitability, analyst recommendations, dividends, media sentiment and valuation. Does the MarketBeat Community prefer GLUE or IOVA? Iovance Biotherapeutics received 555 more outperform votes than Monte Rosa Therapeutics when rated by MarketBeat users. Likewise, 74.45% of users gave Iovance Biotherapeutics an outperform vote while only 48.48% of users gave Monte Rosa Therapeutics an outperform vote. CompanyUnderperformOutperformMonte Rosa TherapeuticsOutperform Votes1648.48% Underperform Votes1751.52% Iovance BiotherapeuticsOutperform Votes57174.45% Underperform Votes19625.55% Which has more risk & volatility, GLUE or IOVA? Monte Rosa Therapeutics has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Does the media favor GLUE or IOVA? In the previous week, Iovance Biotherapeutics had 10 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 13 mentions for Iovance Biotherapeutics and 3 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 1.55 beat Iovance Biotherapeutics' score of 0.60 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Iovance Biotherapeutics 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend GLUE or IOVA? Monte Rosa Therapeutics presently has a consensus price target of $15.50, suggesting a potential upside of 249.89%. Iovance Biotherapeutics has a consensus price target of $18.56, suggesting a potential upside of 474.48%. Given Iovance Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Iovance Biotherapeutics is more favorable than Monte Rosa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monte Rosa Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Iovance Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 Which has better valuation and earnings, GLUE or IOVA? Monte Rosa Therapeutics has higher earnings, but lower revenue than Iovance Biotherapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonte Rosa Therapeutics$75.62M3.60-$135.35M-$1.02-4.34Iovance Biotherapeutics$164.07M6.45-$444.04M-$1.30-2.48 Do institutionals & insiders have more ownership in GLUE or IOVA? 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 6.5% of Monte Rosa Therapeutics shares are owned by insiders. Comparatively, 12.1% of Iovance Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is GLUE or IOVA more profitable? Monte Rosa Therapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -451.25%. Iovance Biotherapeutics' return on equity of -58.43% beat Monte Rosa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Monte Rosa TherapeuticsN/A -62.68% -38.83% Iovance Biotherapeutics -451.25%-58.43%-45.48% SummaryIovance Biotherapeutics beats Monte Rosa Therapeutics on 11 of the 18 factors compared between the two stocks. Remove Ads Get Monte Rosa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLUE vs. The Competition Export to ExcelMetricMonte Rosa TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$272.49M$2.90B$5.33B$7.57BDividend YieldN/A1.91%5.11%4.32%P/E Ratio-2.4231.0021.7217.82Price / Sales3.60441.16376.8894.61Price / CashN/A168.6838.1534.64Price / Book1.243.476.474.00Net Income-$135.35M-$72.06M$3.20B$247.23M7 Day Performance9.11%3.17%2.86%1.45%1 Month Performance-29.35%-16.97%-8.55%-6.24%1 Year Performance-26.90%-29.07%10.58%0.60% Monte Rosa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLUEMonte Rosa Therapeutics3.1069 of 5 stars$4.43+0.5%$15.50+249.9%-32.6%$272.49M$75.62M-2.4290Short Interest ↓Positive NewsGap DownIOVAIovance Biotherapeutics4.2358 of 5 stars$3.03+1.0%$20.25+568.3%-72.8%$993.47M$164.07M-2.03500Analyst ForecastNews CoverageHigh Trading VolumeSNDXSyndax Pharmaceuticals3.3478 of 5 stars$11.01-2.1%$36.20+228.8%-47.6%$947.34M$23.68M-3.03110Gap DownWVEWave Life Sciences4.1709 of 5 stars$5.80-3.8%$22.60+289.7%+9.4%$890.22M$108.30M-5.23240Short Interest ↑Analyst RevisionCOLLCollegium Pharmaceutical4.1683 of 5 stars$27.38-2.7%$43.60+59.2%-22.8%$879.77M$631.45M11.80210Positive NewsGap DownELVNEnliven Therapeutics2.5632 of 5 stars$17.87-4.4%$38.75+116.8%-14.5%$875.70MN/A-9.4150DYNDyne Therapeutics3.5747 of 5 stars$7.49-9.5%$47.46+533.7%-69.1%$847.28MN/A-2.10100GPCRStructure Therapeutics2.5862 of 5 stars$14.31-5.4%$81.29+468.0%-49.8%$820.58MN/A-19.34136News CoverageETNB89bio2.5905 of 5 stars$5.49-4.9%$27.56+401.9%-36.2%$801.45MN/A-1.8940Short Interest ↑High Trading VolumeCMRXChimerix2.9082 of 5 stars$8.52-0.1%$8.53+0.2%+834.8%$799.21M$212,000.00-9.0690Analyst ForecastCDMOAvid Bioservices0.7966 of 5 stars$12.50+0.1%$12.25-2.0%+83.8%$799.18M$139.91M-5.23320Upcoming EarningsHigh Trading Volume Remove Ads Related Companies and Tools Related Companies IOVA Alternatives SNDX Alternatives WVE Alternatives COLL Alternatives ELVN Alternatives DYN Alternatives GPCR Alternatives ETNB Alternatives CMRX Alternatives CDMO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLUE) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
